ValuEngine upgraded shares of Sientra (NASDAQ:SIEN) from a sell rating to a hold rating in a report released on Friday morning.

SIEN has been the subject of a number of other research reports. BidaskClub downgraded shares of Sientra from a hold rating to a sell rating in a research report on Tuesday, January 9th. Canaccord Genuity reissued a buy rating and issued a $19.00 price objective on shares of Sientra in a research report on Friday, January 5th. Stifel Nicolaus raised shares of Sientra from a hold rating to a buy rating and set a $14.00 price objective for the company in a research report on Friday, January 19th. Finally, Zacks Investment Research raised shares of Sientra from a strong sell rating to a hold rating in a research report on Wednesday, January 24th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $15.00.

Sientra (NASDAQ SIEN) opened at $11.68 on Friday. Sientra has a 12-month low of $7.20 and a 12-month high of $16.68. The company has a market cap of $226.54, a PE ratio of -4.10 and a beta of -1.55. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.87 and a quick ratio of 1.92.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.06). Sientra had a negative net margin of 146.46% and a negative return on equity of 116.01%. The firm had revenue of $9.80 million during the quarter, compared to the consensus estimate of $10.54 million. During the same period last year, the business earned ($0.55) EPS. The business’s revenue was up 50.8% on a year-over-year basis. sell-side analysts expect that Sientra will post -3.25 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of SIEN. JPMorgan Chase & Co. acquired a new stake in shares of Sientra during the 2nd quarter worth about $101,000. Nationwide Fund Advisors lifted its stake in shares of Sientra by 260.4% during the 2nd quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 7,921 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Sientra during the 2nd quarter worth about $148,000. Rhumbline Advisers acquired a new stake in shares of Sientra during the 2nd quarter worth about $158,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Sientra by 23.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 18,660 shares of the medical instruments supplier’s stock worth $181,000 after buying an additional 3,534 shares during the last quarter. Institutional investors own 76.72% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sientra (SIEN) Raised to Hold at ValuEngine” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.watchlistnews.com/sientra-sien-raised-to-hold-at-valuengine/1845102.html.

About Sientra

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.